Welcome to our dedicated page for BOUNDLESS BIO news (Ticker: BOLD), a resource for investors and traders seeking the latest updates and insights on BOUNDLESS BIO stock.
Boundless Bio, Inc. develops clinical-stage oncology therapies aimed at oncogene-amplified tumors through extrachromosomal DNA (ecDNA) biology. Its news centers on BBI-940, an oral, selective Kinesin degrader and ecDNA-directed therapeutic candidate, including KOMODO-1 clinical development, preclinical AACR data, FDA IND acceptance, and cancer-model results.
Company updates also cover financial results, cash runway and capital allocation, conference appearances, and portfolio prioritization, including the discontinued POTENTIATE program that combined BBI-355, a CHK1 inhibitor, with BBI-825, an RNR inhibitor.
Boundless Bio (Nasdaq:BOLD) and privately held Serapha Bio signed an all-stock merger agreement. The combined company will be named Serapha Bio and is expected to trade on Nasdaq as “AATD”.
Serapha secured a $230 million concurrent private placement. Pre-merger Boundless holders are expected to own 3.7%, Serapha holders 96.3%. Boundless plans a pre-closing cash dividend of about $44–$48 million. Combined cash is expected to fund SERP-01 into 2H 2029.
Boundless Bio (Nasdaq: BOLD) reported first-quarter 2026 results and program updates on May 8, 2026. Enrollment is ongoing in KOMODO-1, the first-in-human trial of BBI-940 in selected ER+/HER2- and TNBC-LAR breast cancers. AACR 2026 data showed ecDNA reduction and monotherapy tumor regressions in ecDNA+ models. Cash, cash equivalents and short-term investments were $92.8 million as of March 31, 2026, with an expected runway into the second half of 2028.
Q1 operating metrics: R&D $9.7M, G&A $4.7M, and net loss $13.6M.
Boundless Bio (Nasdaq: BOLD) presented preclinical breast cancer data for BBI-940, an oral selective kinesin degrader, at AACR 2026 on April 21, 2026. Findings show genetic and pharmacologic degradation of the novel kinesin caused ecDNA mis-segregation, ecDNA depletion, and reduced viability in ecDNA+ cancer cells.
Key results include 32% sensitivity in breast cancer cell lines, monotherapy tumor regressions in an ecDNA+ TNBC-LAR model, and significant antitumor activity as mono- and combination therapy in an ecDNA+/FGFR1+ ER+ model; BBI-940 is in the Phase 1 KOMODO-1 trial (NCT07408089).
Boundless Bio (Nasdaq: BOLD) will present a poster on its oral Kinesin degrader program at the American Association for Cancer Research Annual Meeting 2026 in San Diego, April 17–22.
The poster covers preclinical work on a novel Kinesin target and the oral degrader BBI-940, which is in the ongoing first‑in‑human KOMODO‑1 trial (NCT07408089) for advanced ER+/HER2‑ and TNBC‑LAR breast cancers. Presentation: April 21, 2026, 2:00–5:00 PM PT, Poster Section 53, Board 18, Abstract LB361.
Boundless Bio (Nasdaq: BOLD) reported Q4 and full-year 2025 results and program updates on March 9, 2026. Key developments: IND for BBI-940 accepted in Jan 2026, KOMODO-1 first-in-human trial is open for enrollment, and POTENTIATE enrollment will cease.
Financials: $107.6M cash as of Dec 31, 2025, runway into the second half of 2028; 2025 net loss $58.2M; R&D $44.8M; G&A $18.7M.
Boundless Bio (Nasdaq: BOLD) announced that President and Chief Executive Officer Zachary Hornby will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida at 11:20 a.m. ET.
A live webcast and archived replay will be accessible via the company’s Investors Events & Presentations page for remote viewing.
Boundless Bio (NASDAQ: BOLD) announced that Zachary Hornby, President and CEO, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 3:00 p.m. ET in New York.
A live and archived webcast will be available in the Investors > Events & Presentations section of the company website.
Boundless Bio (Nasdaq: BOLD) announced FDA acceptance of its IND for BBI-940, a novel Kinesin oral degrader, enabling a first-in-human trial (KOMODO-1) in metastatic breast cancer expected to start in the first half of 2026. The company reported preclinical anti-tumor activity including single-agent tumor regressions in xenograft models and said it expects initial proof-of-concept clinical data within its cash runway. Following portfolio prioritization, Boundless has ceased enrollment in the Phase 1/2 POTENTIATE trial (BBI-355 + BBI-825) and said the revised plan extends its operating runway into the second half of 2028.
Boundless Bio (Nasdaq: BOLD) announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 9:30 a.m. ET in New York, NY.
A live and archived webcast will be available in the Events & Presentations section of Boundless Bio's Investors website.
Boundless Bio (Nasdaq: BOLD) reported third quarter 2025 results and program updates on Nov 5, 2025. The company had $117.6 million in cash, cash equivalents, and short-term investments as of Sept 30, 2025, stated to support operations into the first half of 2028. Enrollment is ongoing in the BBI-355/BBI-825 combination arm of the Phase 1/2 POTENTIATE trial. An IND submission for BBI-940 is on track and a first-in-human Phase 1 trial is expected in the first half of 2026. Q3 2025 results: R&D $10.7M (Q3 2024: $14.1M), G&A $4.5M (Q3 2024: $4.6M), and net loss $13.9M (Q3 2024: $16.5M).